IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit:				
STAMP) Examiner:				
Serial No.: NOT YET ASSIGNED) INFORMATION DISCLOSURE STATEMENT				
Filed: HEREWITH))				
Atty. File No.: 7095MH-5)				
For: "INJECTION DEVICE")				
Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Dear Sir:					
The references cited on attached For	m PTO-SB08 are being called to the attention of the				
Examiner.					
☐ Copies of the cited non-paten	Copies of the cited non-patent and/or foreign references are enclosed herewith.				
☐ Copies of the cited U.S. pater	Copies of the cited U.S. patents and/or patent applications are enclosed herewith.				
☐ Copies of the cited U.S. pater	Copies of the cited U.S. patents/patent application publications are not enclosed in				
accordance with 37 C.F.R. § 1.98(a).					
□ Copies of the cited reference	es are not enclosed, in accordance with 37 C.F.R.				
§ 1.98(d), because the references were cited by	y or submitted to the U.S. Patent and Trademark Office				
in prior application Serial No.	filed, which is relied upon for an				
earlier filing date under 35 U.S.C. § 120.					
☐ To the best of applicants' belief	ef, the pertinence of the foreign-language references are				
believed to be summarized in the attached Er	nglish abstracts and in the figures, although applicants				
do not necessarily vouch for the accuracy of	the translation.				
☐ Examiner's attention is drawn	n to the following co-pending applications, copies of				
which have been or are being submitted:					
Serial No.	filed				

	Serial No filed
\boxtimes	Other: PCT International Preliminary Report on Patentability dated January 23, 2006
for Applicatio	n No. PCT/GR2005/000223

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

×	37 CFR 1.97(b): No fee is believed due in connection w submitted herewith is satisfies one of the following cond	ith this submission, because the information disclosure statement itions ("X" indicates satisfaction):						
	Within three months of the filing application under 37 CFR 1.53(d)	date of a national application other than a continued prosecution, or						
	Within three months of the date of forth in 37 CFR 1.491 or	of entry into the national stage of an international application as set						
	☐ Before the mailing date of a first	Office Action on the merits, or						
	Before the mailing of a first Offic 37 CFR 1.114.	e action after the filing of a request for continued examination under						
	Although no fee is believed due, if any fee is deemed du Deposit Account 19-1970.	e in connection with this submission, please charge such fee to						
	37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by:							
	A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR							
	Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.							
	37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c). This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND							
	Account 19-1970 in the amount of \$180.00 under 37 C.	of the reference(s) disclosed herein. Please charge Deposit F.R. 1.17(p). Please credit any overpayment or charge any pay the fee should not be taken as an indication that applicant(s)						

Certification (37 C.F.R. 1.97(e)) (Applicable only if checked) The undersigned certifies that: Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1). A copy of the communication from the foreign patent office is enclosed. OR No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,

SHERIDAN ROSS P.C.

Bradley M. Knepper

Registration No. 44,189

1560 Broadway, Suite 1200 Denver, Colorado 80202-5141

(303) 863-9700

-3-

Date: July 21, 2006

	Application Number		
INFORMATION DIOCE COLUDE	Filing Date		2006-07-21
INFORMATION DISCLOSURE	First Named Inventor Stam		p
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
(not for submission under or or it masy	Examiner Name		
	Attorney Docket Number		7095MH-5

	U.S.PATENTS R					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6544234		2003-04-08	Gabriel	
	2	5681291		1997-10-28	Galli	
	3	4913699		1990-04-03	Parsons	
	4	6264629		2001-07-24	Landau	
	5	4617016		1986-10-14	Blomberg	
	6	5779675		1998-07-14	Reilly et al.	
	7	5078698		1992-01-07	Stiehl et al.	
	8	3811442		1974-05-21	Maroth	

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-07-21
First Named Inventor	Stam	р
Art Unit		
Examiner Name		
Attorney Docket Number		7095MH-5

	9	5568261		1997-08	3-19	Neer et al.					
	10	6752781		2004-06	6-22	Landau et al.					
If you wisl	h to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P.	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20030093030		2003-05	5-15	Landau					
	2	20010053886		2001-12-20		Caizza					
	3	20030045858		2003-03-06		Struys et al.					
	4	20010004681		2001-06-21		Landau, Sergi	0				
	5	20030000524		2003-01-02		Anderson, Gre McLennan; et					
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e or V F	vhere Rele	or Relevant	T5

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-07-21
First Named Inventor	Stam	p
Art Unit		
Examiner Name		
Attorney Docket Number		7095MH-5

	1	03097133	WO		2006-07-18	Owen Mumford Limited			
	2	0009186	wo		2000-02-24	Medi-Ject Corporation			
	3	1323447	EP		2003-08-13	Becton, Dickinson and Company			
	4	0453212	EP		1991-04-15	Pacesetter Infusion Limited d/b/a Minimed Tech.			
	5	886444	GB		1962-01-10	American Home Products Corporation			
	6	2005/097252	WO		2005-10-20	Medrad, Inc.			
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	n Add		
			NON-PATEN	IT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), c	the article (when approposition and the contract of the contra		T5	
	1	PCT International Preliminary Report on Patentability dated January 23, 2006 for Application No. PCT/GB2005/000223.							
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Signa	ture				Date Considered			
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-07-21
First Named Inventor	Stam	p
Art Unit		
Examiner Name		
Attorney Docket Number		7095MH-5

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-07-21
First Named Inventor	Stam	р
Art Unit		
Examiner Name		
Attorney Docket Number		7095MH-5

		CERTIFICATION	N STATEMENT				
Plea	ase see 37 CFR 1	.97 and 1.98 to make the appropriate select	ion(s):				
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	!						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).						
	See attached cer	rtification statement.					
	Fee set forth in 3	7 CFR 1.17 (p) has been submitted herewit	h.				
✓	None						
		SIGNA	TURE				
	ignature of the ap n of the signature.	plicant or representative is required in accor	dance with CFR 1.33, 10.1	18. Please see CFR 1.4(d) for the			
Sigr	nature	/Bradley M. Knepper/	Date (YYYY-MM-DD)	2006-07-21			
Nan	Name/Print Bradley M. Knepper Registration Number 44189						
pub 1.14	lic which is to file of the fi	mation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an application s estimated to take 1 hour to complete, included USPTO. Time will vary depending upon the	on. Confidentiality is gover uding gathering, preparing	rned by 35 U.S.C. 122 and 37 CFR and submitting the completed			

require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

EFS Web 1.0

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.